DDInter1055 DDInter1036
Levofloxacin is a fluoroquinolone antibiotic and the optical S-(-) isomer of racemic [ofloxacin]. It reportedly carries 8 to 128-fold more activity against both gram-negative and gram-positive bacteria compared to R-(+)-ofloxacin and remains stereochemically stable following administration (i.e. it does not invert to the inactive isomer). Levofloxacin, along with other quinolones such as [gatifloxacin] and [moxifloxacin], is a member of the third generation of fluoroquinolones, colloquially referred to as the "respiratory quinolones" due to improved activity against gram-positive bacteria commonly implicated in respiratory infections.[A31453,A190756] Levofloxacin was first approved by the FDA in 1996, and was approved in Canada and several South American countries soon after.
Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; the platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET. These receptor tyrosine kinases (RTKs) located in the cell membrane play a central role in the activation of signal transduction pathways involved in the normal regulation of cellular processes, such as cell proliferation, migration, apoptosis and differentiation, and in pathogenic angiogenesis, lymphogenesis, tumour growth and cancer progression. In particular, VEGF has been identified as a crucial regulator of both physiologic and pathologic angiogenesis and increased expression of VEGF is associated with a poor prognosis in many types of cancers. Lenvatinib is indicated for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine (RAI)-refractory differentiated thyroid cancer. Most patients with thyroid cancer have a very good prognosis with treatment (98% 5 year survival rate) involving surgery and hormone therapy. However, for patients with RAI-refractory thyroid cancer, treatment options are limited and the prognosis is poor, leading to a push for the development of more targeted therapies such as lenvatinib.
Levofloxacin {u} (Compound) resembles {v} (Compound) Ofloxacin
Ofloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lenvatinib
Levofloxacin {u} (Compound) resembles {v} (Compound) Moxifloxacin
Moxifloxacin {u} may lead to a major life threatening interaction when taken with {v} Lenvatinib
Levofloxacin {u} (Compound) resembles {v} (Compound) Sparfloxacin
Sparfloxacin {u} may lead to a major life threatening interaction when taken with {v} Lenvatinib
Levofloxacin {u} (Compound) resembles {v} (Compound) Ofloxacin
Ofloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Metronidazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lenvatinib
Levofloxacin {u} (Compound) resembles {v} (Compound) Moxifloxacin
Moxifloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Metronidazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lenvatinib
Levofloxacin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Metronidazole
Metronidazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lenvatinib
Levofloxacin {u} (Compound) resembles {v} (Compound) Sparfloxacin
Sparfloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Metronidazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lenvatinib
Levofloxacin {u} (Compound) resembles {v} (Compound) Ofloxacin
Ofloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clarithromycin
Clarithromycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lenvatinib
Levofloxacin {u} (Compound) resembles {v} (Compound) Moxifloxacin
Moxifloxacin {u} may lead to a major life threatening interaction when taken with {v} Clarithromycin
Clarithromycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lenvatinib
Levofloxacin {u} (Compound) causes {v} (Side Effect) Encephalopathy
Encephalopathy {u} (Side Effect) is caused by {v} (Compound) Metronidazole
Metronidazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lenvatinib
Levofloxacin (Compound) resembles Ofloxacin (Compound) and Ofloxacin may cause a moderate interaction that could exacerbate diseases when taken with Lenvatinib
Levofloxacin (Compound) resembles Moxifloxacin (Compound) and Moxifloxacin may lead to a major life threatening interaction when taken with Lenvatinib
Levofloxacin (Compound) resembles Sparfloxacin (Compound) and Sparfloxacin may lead to a major life threatening interaction when taken with Lenvatinib
Levofloxacin (Compound) resembles Ofloxacin (Compound) and Ofloxacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lenvatinib
Levofloxacin (Compound) resembles Moxifloxacin (Compound) and Moxifloxacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lenvatinib
Levofloxacin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Metronidazole (Compound) and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lenvatinib
Levofloxacin (Compound) resembles Sparfloxacin (Compound) and Sparfloxacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lenvatinib
Levofloxacin (Compound) resembles Ofloxacin (Compound) and Ofloxacin may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Lenvatinib
Levofloxacin (Compound) resembles Moxifloxacin (Compound) and Moxifloxacin may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Lenvatinib
Levofloxacin (Compound) causes Encephalopathy (Side Effect) and Encephalopathy (Side Effect) is caused by Metronidazole (Compound) and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lenvatinib